BOSTON --(BUSINESS WIRE)--Sep. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small

Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a.m.

HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 2, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences: A fireside chat presentation at the

Reduced circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) levels were associated with tumor shrinkage in patients that responded to poziotinib treatment Poziotinib has received Fast Track designation from FDA and a Prescription Drug User Fee Act (PDUFA) date of November 24, 2022

HENDERSON, Nev. --(BUSINESS WIRE)--May 17, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference , to be held

Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2

HENDERSON, Nev. --(BUSINESS WIRE)--May 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022 . Ms.

HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update

HENDERSON, Nev. --(BUSINESS WIRE)--May 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years

FDA has assigned September 9, 2022 as the PDUFA date HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA)

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 4, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR)

Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 10, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors. “We are delighted to have Ms.

Data presented at ESMO TAT from Cohort 4 of the ZENITH20 clinical trial met the primary endpoint HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 7, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 28, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S.

HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 20, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the B. Riley Securities 2022 Virtual Oncology Conference .

Workforce reduction of approximately 30% Cash runway extended into 2023 Resources to be focused on late-stage assets, poziotinib and ROLONTIS ® HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted